PLUR Pluri Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1158780 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY10.0%
TTM net income YoY-25.8%
TTM EPS YoY15.7%
Revenue 3-yr CAGR79.1%
Net income 3-yr CAGR—
Margins
Gross margin52.0%
Operating margin-2,341.1%
Net margin-1,943.9%
FCF margin-1,317.8%
EBITDA margin-2,306.0%
Returns
ROE—
ROA-96.8%
ROIC (approx.)—
Asset turnover0.05x
Leverage & solvency
Liabilities / assets167.1%
Debt / equity—
Current ratio0.27x
Interest coverage-36.77x
Cash quality & payout
Operating cash flow / net income0.66x
Accruals ratio-33.0%
Payout ratio—
Capex / revenue35.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 | FY20242024-06-30 | FY20232023-06-30 | FY20222022-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.02M | $1.34M | $326,000 | $287,000 | $234,000 |
| Cost of revenue | $563,000 | $682,000 | $4,000 | $9,000 | — |
| Gross profit | $453,000 | $654,000 | $322,000 | $278,000 | $234,000 |
| R&D expense | $15.09M | $12.85M | $12.45M | $15.74M | $24.61M |
| SG&A expense | $10.30M | $9.98M | $10.03M | $11.78M | $17.45M |
| Operating income | -$24.94M | -$22.18M | -$22.16M | -$27.25M | -$41.59M |
| Interest expense | $932,000 | $873,000 | $866,000 | $843,000 | $887,000 |
| Pretax income | -$25.39M | -$23.25M | -$21.34M | — | — |
| Income tax | -$25,000 | -$5,000 | — | — | — |
| Net income | -$23.82M | -$22.58M | -$20.89M | -$28.32M | -$41.24M |
| EBITDA | -$24.43M | -$21.86M | -$21.91M | -$26.88M | -$40.54M |
| EPS (basic) | -2.44 | -3.56 | -3.99 | -6.24 | -1.28 |
| EPS (diluted) | -2.44 | -3.56 | -3.99 | -6.24 | -1.28 |
| Weighted avg. shares (diluted) | 9.74M | 6.34M | 5.24M | 4.58M | 32.19M |
| Balance sheet | |||||
| Cash & equivalents | $3.53M | $7.20M | $7.67M | $6.26M | $11.41M |
| Receivables | — | — | — | — | $3,000 |
| Current assets | $8.73M | $22.09M | $31.11M | $41.41M | $57.75M |
| PP&E, net | $1.57M | $1.82M | $688,000 | $688,000 | $739,000 |
| Goodwill | $3.14M | $3.14M | — | — | — |
| Intangibles | $2.61M | $2.79M | — | — | — |
| Total assets | $24.88M | $38.68M | $39.53M | $50.80M | $68.06M |
| Current liabilities | $32.72M | $32.33M | $4.45M | $5.62M | $6.83M |
| Total liabilities | $42.31M | $39.55M | $34.11M | $35.50M | $35.88M |
| Shareholders' equity | -$23.04M | -$6.84M | $96,000 | $13.36M | $30.04M |
| Shares outstanding | 10.82M | 7.89M | 5.41M | 5.16M | 32.51M |
| Cash flow statement | |||||
| Operating cash flow | -$19.59M | -$18.21M | -$18.02M | -$22.86M | -$36.50M |
| Capital expenditure | $633,000 | $1.62M | $323,000 | $262,000 | $280,000 |
| Free cash flow | -$20.22M | -$19.83M | -$18.34M | -$23.12M | -$36.78M |
| Investing cash flow | $9.90M | $8.03M | $10.58M | $9.70M | $11.78M |
| Financing cash flow | $7.04M | $9.53M | $8.84M | $8.02M | $7.50M |
| Depreciation & amortization | $511,000 | $316,000 | $253,000 | $362,000 | $1.05M |
| Stock-based compensation | $3.73M | $2.14M | $2.62M | $3.98M | $8.91M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.